

# Giovanni Orsolini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9153531/publications.pdf>

Version: 2024-02-01

57  
papers

872  
citations

516561

16  
h-index

526166

27  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1157  
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteoporosis in Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5867.	1.8	76
2	Bone Involvement and Osteoporosis in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 383-396.	0.7	72
3	Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients. <i>Calcified Tissue International</i> , 2017, 101, 17-23.	1.5	52
4	In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 77-83.	0.4	50
5	Association between environmental air pollution and rheumatoid arthritis flares. <i>Rheumatology</i> , 2021, 60, 4591-4597.	0.9	43
6	Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. <i>Bone</i> , 2016, 92, 150-156.	1.4	40
7	Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis. <i>Calcified Tissue International</i> , 2016, 99, 360-364.	1.5	39
8	Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. <i>Rheumatology International</i> , 2015, 35, 255-263.	1.5	34
9	Zoledronic Acid in Osteoporosis Secondary to Mastocytosis. <i>American Journal of Medicine</i> , 2014, 127, 1127.e1-1127.e4.	0.6	31
10	Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis. <i>Pharmacological Research</i> , 2019, 147, 104354.	3.1	30
11	Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study. <i>RMD Open</i> , 2022, 8, e002055.	1.8	29
12	Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series. <i>Calcified Tissue International</i> , 2017, 100, 595-598.	1.5	26
13	Bone Disease in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 443-454.	0.7	25
14	An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 1059-1062.	0.9	25
15	Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis. <i>Calcified Tissue International</i> , 2016, 98, 580-585.	1.5	21
16	Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1386-1388.	2.0	21
17	Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment. <i>Frontiers in Medicine</i> , 2020, 7, 613720.	1.2	18
18	The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders. <i>Frontiers in Endocrinology</i> , 2021, 12, 620920.	1.5	18

#	ARTICLE	IF	CITATIONS
19	Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1848-1859.	0.8	16
20	Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2018, 37, 3093-3098.	1.0	16
21	A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Yearsâ€™ Experience of the GISM Network. <i>Cancers</i> , 2021, 13, 6380.	1.7	16
22	Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. <i>Endocrine</i> , 2015, 49, 620-627.	1.1	14
23	Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis?. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2142-2143.	3.1	14
24	Vitamin D serum levels and the risk of digital ulcers in systemic sclerosis: A longitudinal study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1041-1045.	0.9	13
25	Environmental Air Pollution Is a Predictor of Poor Response to Biological Drugs in Chronic Inflammatory Arthritides. <i>ACR Open Rheumatology</i> , 2021, 3, 451-456.	0.9	13
26	SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021068.	0.5	13
27	Bone Marrow Mastocytosis: A Diagnostic Challenge. <i>Journal of Clinical Medicine</i> , 2021, 10, 1420.	1.0	12
28	Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease. <i>Clinical Rheumatology</i> , 2017, 36, 2487-2495.	1.0	11
29	Antiâ€™phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an allâ€™omer population. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2070-2074.	1.9	9
30	Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement. <i>Clinical Rheumatology</i> , 2020, 39, 727-736.	1.0	8
31	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. <i>Cancers</i> , 2019, 11, 30.	1.7	7
32	Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e150-e150.	0.5	7
33	Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 570-571.	3.1	7
34	Rheumatoid arthritis, Î³Î³ T cells and bisphosphonates. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e57-e57.	0.5	5
35	Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 863-874.	1.0	5
36	Immunoglobulin G4-Related Disease Responder Index Correlates With the Risk of 1-Year Relapse in Type 1 Autoimmune Pancreatitis. <i>Pancreas</i> , 2021, 50, 879-881.	0.5	5

#	ARTICLE	IF	CITATIONS
37	Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e166-e166.	0.5	4
38	Correspondence on "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e222-e222.	0.5	4
39	Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 158.	1.6	4
40	Anti-CCP antibodies and bone. <i>Arthritis Research and Therapy</i> , 2018, 20, 63.	1.6	3
41	Sex-Specific Association of Left Ventricular Hypertrophy With Rheumatoid Arthritis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 676076.	1.1	3
42	Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. <i>Arthritis Research and Therapy</i> , 2018, 20, 233.	1.6	2
43	Usefulness of CHA2DS2-VASc score to predict mortality and hospitalization in patients with inflammatory arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 106-115.	0.9	2
44	Could Previous Exposure to Nitrogen-Containing Bisphosphonates Mitigate Friendly Fire?. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 2082-2082.	3.1	2
45	Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?". <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2943-2944.	2.0	2
46	Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211050.	1.2	2
47	Incidence and predictors of adverse clinical events in patients with rheumatoid arthritis and asymptomatic left ventricular systolic dysfunction. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 420-427.	0.4	1
48	Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 344-350.	0.4	1
49	Cardiovascular morbidity and mortality in patients with rheumatic disease: hyperuricemia, a forgotten puzzle piece?. <i>Clinical Rheumatology</i> , 2017, 36, 2869-2870.	1.0	0
50	FRIO469...CHANGES IN DKK-1, SCLEROSTIN, AND RANKL SERUM LEVELS FOLLOWING DISCONTINUATION OF LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN. , 2019, , .		0
51	OPO230...EFFECTIVENESS OF INFLUENZA VACCINE IN TNF INHIBITORS TREATED PATIENTS. , 2019, , .		0
52	FRIO045...CHANGES IN LEFT VENTRICULAR SYSTOLIC FUNCTION ARE PREDICTED BY DISEASE SEVERITY IN PATIENTS WITH RHEUMATOID ARTHRITISWITHOUT PRIOR CARDIOVASCULAR DISEASE. , 2019, , .		0
53	AB0641...VITAMIN D SERUM LEVELS AND THE RISK OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A LONGITUDINAL STUDY. , 2019, , .		0
54	Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 510-518.	0.9	0

#	ARTICLE	IF	CITATIONS
55	The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2021, 23, 89.	1.6	0
56	Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 344-350.	0.4	0
57	Is there Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Real-World Paired Serum and Plasma Testing. <i>Thrombosis and Haemostasis</i> , 0, , .	1.8	0